DK0484112T3 - Anvendelse af lithium ved behandlingen eller profylakse af Molluscum contagiosum - Google Patents

Anvendelse af lithium ved behandlingen eller profylakse af Molluscum contagiosum

Info

Publication number
DK0484112T3
DK0484112T3 DK91309994.1T DK91309994T DK0484112T3 DK 0484112 T3 DK0484112 T3 DK 0484112T3 DK 91309994 T DK91309994 T DK 91309994T DK 0484112 T3 DK0484112 T3 DK 0484112T3
Authority
DK
Denmark
Prior art keywords
prophylaxis
treatment
molluscum contagiosum
lithium
lithium compound
Prior art date
Application number
DK91309994.1T
Other languages
Danish (da)
English (en)
Inventor
David Frederick Horrobin
Original Assignee
Scotia Holdings Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc
Application granted granted Critical
Publication of DK0484112T3 publication Critical patent/DK0484112T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Glass Compositions (AREA)
  • Materials For Medical Uses (AREA)
DK91309994.1T 1990-10-31 1991-10-30 Anvendelse af lithium ved behandlingen eller profylakse af Molluscum contagiosum DK0484112T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909023701A GB9023701D0 (en) 1990-10-31 1990-10-31 Medical treatment

Publications (1)

Publication Number Publication Date
DK0484112T3 true DK0484112T3 (da) 1995-09-18

Family

ID=10684665

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91309994.1T DK0484112T3 (da) 1990-10-31 1991-10-30 Anvendelse af lithium ved behandlingen eller profylakse af Molluscum contagiosum

Country Status (11)

Country Link
US (1) US5223271A (de)
EP (1) EP0484112B1 (de)
JP (1) JPH06263644A (de)
AT (1) ATE126061T1 (de)
AU (1) AU645359B2 (de)
CA (1) CA2052246A1 (de)
DE (1) DE69111974T2 (de)
DK (1) DK0484112T3 (de)
GB (1) GB9023701D0 (de)
GR (1) GR3017855T3 (de)
IE (1) IE71171B1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756107A (en) * 1994-12-21 1998-05-26 Cosmederm Technologies Formulations and methods for reducing skin irritation
US7404967B2 (en) 1994-12-21 2008-07-29 Cosmederm, Inc. Topical product formulations containing strontium for reducing skin irritation
US5840711A (en) * 1995-06-21 1998-11-24 University Of Kentucky Research Foundation Compositions containing lithium inorganic salts and anti-viral drugs and method of treating viral infections such as acquired immunodeficiency syndrome
ATE373957T1 (de) * 1997-10-09 2007-10-15 Univ Emory Verfahren und vorrichtung zur transdermalen verabreichung von lithium
FR2783424B1 (fr) * 1998-09-03 2002-10-04 Labcatal Utilisation du gluconate de lithium dans la fabrication d'un medicament pour le traitement de l'herpes et de la dermite seborrheique
DE60023180D1 (de) * 1999-12-30 2006-02-23 Henderson Morley Res & Dev Ltd Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und lithium enthalten
ES2164018B1 (es) * 2000-05-26 2003-06-16 Inst De Salud Carlos Iii Empleo de una sal de litio en la elaboracion de un medicamento para el tratamiento de la infeccion causada por el virus respiratorio sincitial humano (vrdh)
US7311928B2 (en) * 2003-12-09 2007-12-25 Briant Burke Topical compositions containing tea tree oil for treatment of viral lesions
EP2143421A1 (de) * 2008-07-07 2010-01-13 Almirall Hermal GmbH Zusammensetzung zur topischen Behandlung von Strahlenkeratose
EP2648676A4 (de) 2010-12-06 2016-05-04 Follica Inc Verfahren zur behandlung von kahlköpfigkeit und zur förderung des haarwuchses
WO2012125941A1 (en) * 2011-03-17 2012-09-20 Follica, Inc. Lithium treatment for microbial infections
JP6595454B2 (ja) * 2013-05-03 2019-10-23 リピドール エービー 薬学的又は化粧学的活性成分を投与するための局部用組成物及びキャリアー
US20220347208A1 (en) * 2019-06-19 2022-11-03 Carl Ganio Formulations using lithium to treat gout arthropathy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639625A (en) * 1967-07-13 1972-02-01 Lewis Sherwin Compositions containing lithium succinate
US4396452A (en) 1978-12-21 1983-08-02 Monsanto Company Process for point-bonding organic fibers
JPS5590505A (en) 1978-12-29 1980-07-09 Kureha Chem Ind Co Ltd Carboxyalkylchitin and preparation of deacetylated product thereof
US4328243A (en) * 1981-04-07 1982-05-04 Horrobin David F Manic-depressive illnesses
US4386072A (en) * 1981-06-26 1983-05-31 Horrobin David F Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor
AU556817B2 (en) * 1982-02-03 1986-11-20 Efamol Limited Topical application of a lithium salt and dihomo-alpha- linolenic acid
GB8318912D0 (en) * 1983-07-13 1983-08-17 Horrobin D F Compositions for treatment of skin/hair
GB8320203D0 (en) * 1983-07-27 1983-09-01 Horrobin D F Anti-viral compositions
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
GB8719988D0 (en) * 1987-08-25 1987-09-30 Efamol Ltd Chemical compounds
EP0289204B1 (de) * 1987-04-27 1991-07-17 Efamol Holdings Plc Lithiumsalze enthaltende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
DE69111974D1 (de) 1995-09-14
IE71171B1 (en) 1997-01-29
US5223271A (en) 1993-06-29
GR3017855T3 (en) 1996-01-31
CA2052246A1 (en) 1992-05-01
EP0484112A2 (de) 1992-05-06
AU645359B2 (en) 1994-01-13
DE69111974T2 (de) 1996-01-04
AU8687391A (en) 1992-05-07
JPH06263644A (ja) 1994-09-20
EP0484112B1 (de) 1995-08-09
IE913787A1 (en) 1992-05-22
EP0484112A3 (en) 1992-07-08
GB9023701D0 (en) 1990-12-12
ATE126061T1 (de) 1995-08-15

Similar Documents

Publication Publication Date Title
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
NO931267D0 (no) Fremgangsmaate for behandling eller forebyggelse av type 1diabetes ved oral administrering av insulin
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
MX9203543A (es) Medicamento.
ES554967A0 (es) Un procedimiento para preparar una formulacion farmaceutica que contiene un 2'3'-didesoxi-nucleosido.
DE58901401D1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
BR9303469A (pt) Conjugado de interferon,composto,processo de preparacao de um conjugado de interferon,use e composicoes farmaceuticas
ES2090244T3 (es) Procedimiento para prevenir, estabilizar u ocasionar la regresion de la aterosclerosis usando una combinacion de un medicamento para disminuir el colesterol y un inhibidor de la ace.
DK0484112T3 (da) Anvendelse af lithium ved behandlingen eller profylakse af Molluscum contagiosum
DE69333387D1 (de) Pharmazeutische Zusammensetzungen enthaltend Norastemizol.
DE69133077D1 (de) Herstellung von ST1435 enthaltenden pharmazeutischen Zusammensetzungen zur topischen Verwendung
DE69835461D1 (de) Anti-arrhythmische Zusammensetzungen und Behandlungsverfahren
DK347289A (da) Terapeutiske forbindelser
SE8804640D0 (sv) Medicament comprising cyclolinopeptide a
NO993921D0 (no) Medikament mot infertilitet og for ökt fertilitet
ES2120966T3 (es) 1'-aminoespiro(isoquinolino-4(1h),3'-pirrolidino)-1,2',3,5'(2h)-tetronas y analogos de las mismas utiles como inhibidores de la aldosa reductasa in vivo.
MX9303074A (es) Uso de la (e)-2-(p-fluorofenetil)-3-fluoroalilamina en el tratamiento de la enfermedad de elzheimer.
SE8903117D0 (sv) Laekemedel omfattande antamanid
IT1243368B (it) Uso del bendazac e dei suoi sali farmaceuticamente accettabili
UY26292A1 (es) Micofenolato mofetilo en asociacion con peg-ifn-a ley 17164